Volume 60, Issue 4, Pages (October 2011)

Slides:

Advertisements

Similar presentations

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Advertisements

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis Maria I. Carlo, Darren R.

Volume 55, Issue 2, Pages (February 2009)

Renal Cell Carcinoma: Prognostic Factors and Patient Selection

Volume 71, Issue 2, Pages (February 2017)

Volume 73, Issue 1, Pages (January 2018)

Volume 51, Issue 1, Pages (January 2007)

Volume 73, Issue 3, Pages (March 2018)

Volume 69, Issue 1, Pages 4-6 (January 2016)

Lymph Node Dissection in Renal Cell Carcinoma

Histologic Grading of Noninvasive Papillary Urothelial Neoplasms

Ziya Kirkali, Hein Van Poppel European Urology

Volume 54, Issue 4, Pages (October 2008)

New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006 Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz,

Let the Games Begin (with EAU Approval)

Volume 68, Issue 1, Pages (July 2015)

Prostate Cancer Epidemic in Sight?

Volume 60, Issue 4, Pages (October 2011)

Volume 73, Issue 4, Pages e116-e118 (April 2018)

Giuseppe Di Lorenzo, Riccardo Autorino, Cora N. Sternberg

Neeraj Agarwal, Guru Sonpavde, Cora N. Sternberg European Urology

Toxicities of Targeted Therapy and Their Management in Kidney Cancer

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 66, Issue 2, Pages (August 2014)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 52, Issue 5, Pages (November 2007)

Volume 72, Issue 4, Pages (October 2017)

Volume 55, Issue 2, Pages (February 2009)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Obesity and Prostate Cancer: A Role for Adipokines

Volume 56, Issue 2, Pages (August 2009)

Volume 60, Issue 5, Pages (November 2011)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Prostate Cancer Epidemic in Sight?

Volume 65, Issue 6, Pages (June 2014)

Volume 50, Issue 3, Pages (September 2006)

Volume 64, Issue 4, Pages (October 2013)

Volume 74, Issue 3, Pages (September 2018)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 59, Issue 1, Pages (January 2011)

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.

Volume 68, Issue 4, Pages (October 2015)

Volume 56, Issue 5, Pages (November 2009)

Volume 47, Issue 1, Pages (January 2005)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 62, Issue 3, Pages (September 2012)

Volume 71, Issue 2, Pages (February 2017)

Basic Research in Kidney Cancer

Volume 50, Issue 5, Pages (November 2006)

Mammalian Target of Rapamycin Inhibitors in Clinical Practice: Case Reports of Everolimus in Renal Cell Carcinoma Sergio Bracarda, Alain Ravaud, Marino.

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 73, Issue 4, Pages e116-e118 (April 2018)

Testicular Cancer Variations in Time and Space in Europe

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response.

Volume 54, Issue 4, Pages (October 2008)

Bernard Escudier European Urology Supplements

Sergio Bracarda European Urology Supplements

European Urology is “Your” Journal

Epidemiology of Renal Cell Carcinoma

Volume 51, Issue 6, Pages (June 2007)

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Annika Berntsen, Poul F. Geertsen, Inge Marie Svane European Urology

Joaquim Bellmunt European Urology Supplements

Jan Roigas European Urology Supplements

Update on the Medical Treatment of Metastatic Renal Cell Carcinoma

Volume 51, Issue 5, Pages (May 2007)

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma Guillermo de Velasco, Axel Bex, Laurence Albiges, Thomas Powles, Brian.

Presentation transcript:

Volume 60, Issue 4, Pages 684-690 (October 2011) ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease Jean-Jacques Patard, Geraldine Pignot, Bernard Escudier, Tim Eisen, Axel Bex, Cora Sternberg, Brian Rini, Jan Roigas, Toni Choueiri, Ronald Bukowski, Robert Motzer, Ziya Kirkali, Peter Mulders, Joaquim Bellmunt European Urology Volume 60, Issue 4, Pages 684-690 (October 2011) DOI: 10.1016/j.eururo.2011.06.017 Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 1 Treatment schematic for patients with metastatic clear-cell renal cell carcinoma in the first-line setting. IL-2=interleukin-2; IFN-α=interferon-α. European Urology 2011 60, 684-690DOI: (10.1016/j.eururo.2011.06.017) Copyright © 2011 European Association of Urology Terms and Conditions

Fig. 2 Treatment schematic for patients with metastatic clear-cell renal cell carcinoma in the second-line setting. VEGF=vascular endothelial growth factor; mTOR=mammalian target of rapamycin; TKI=multi–tyrosine kinase inhibitor. European Urology 2011 60, 684-690DOI: (10.1016/j.eururo.2011.06.017) Copyright © 2011 European Association of Urology Terms and Conditions